|
Found 25 result(s) FROM 1963 pages containing the term 'comorbidities'.
Wednesday Aug 05, 2009
Psoriasis: Not Just Skin Deep
Mark G. Lebwohl, MD says psoriasis affects the heart and other vital organs, and treatment with TNF-blockers may reduce the risk of these comorbidities...
Thursday Jun 04, 2009
Allopurinol Extends Gout Survival
Gout patients who take allopurinol live longer than those who do not, mostly due to decreased cardiovascular mortality...
Tuesday May 12, 2009
Obesity, Arthritis Blamed for Disability in Women
Females are at greater risk of obesity and arthritis than their male counterparts and these disabling conditions begin early and can rob women of their quality of life...
Wednesday Nov 12, 2008
Pegloticase Offers Hope to Patients With Worst Types of Gout
Pegloticase (Puricase®, Savient Pharmaceuticals, Inc.) performed well in two Phase III studies...
Tuesday May 20, 2008
Is "Diarthritis" the New Epidemic? Maybe
We've heard of diabesity (the converging epidemic of diabetes and obesity) and now doctors may be seeing more diarthritis (diabetes plus arthritis) in their patients…
Monday Mar 10, 2008
Avoidable Hospitalizations Common Among Older, Poorer SLE Patients
Rheumatologists have a key role in preventing avoidable hospitalizations among older, poorer patients with systemic lupus erythematosus (SLE)…
Thursday Dec 20, 2007
New EULAR Recommendations on Systemic Glucocorticoids Stress Monitoring for Adverse Events
EULAR has issued new evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases...
Wednesday Sep 05, 2007
Rheumatologists Asked to Take Lead in Reducing Cardiovascular Risk in RA Patients
The chronic inflammation that characterizes many rheumatoid diseases is thought to be one cause of the higher rates of cardiovascular disease (CVD) that afflicts these patients. Experts say not enough is being done to educate patients with rheumatoid arthritis (RA) or with systemic lupus erythematosus (SLE) about the importance of early CV protection, and that early education is critical—before clinically apparent CVD is detectable...van Leuven SI, et al. Rheumatology. 2007; rheumatology/kem202 [Epub ahead of print]; John H, et al. Rheumatology. 2007; doi:10.1093/rheumatology/kem176 [Epub ahead of print].
Tuesday Aug 28, 2007
Diseased Blood Vessels in the Bone May Cause or Aggravate OA
Vascular pathology may play a role in the pathogenesis or progression of osteoarthritis…Findlay DM. Rheumatology. 2007; doi:10.1093/rheumatology/kem191 [Epub ahead of print].
Thursday Jul 05, 2007
Too Much Early, Aggressive Care Slows Recovery From Whiplash
Early, aggressive treatment of whiplash impedes recovery, and adding chiropractic to general medical care slows recuperation even more...
Friday Jun 15, 2007
Two Thirds of Gout Patients Receiving No, or Not Enough Treatment
A number of new treatment options for gout are available, but the major clinical problem is that even after gout diagnosis, only about one third of patients receive urate-lowering therapy...
Thursday May 24, 2007
Is Mycophenolate Mofetil Plus Steroid Now Standard Therapy for Lupus Nephritis?
Mycophenolate mofetil plus corticosteroids may emerge as the de facto standard for lupus nephritis, even without regulatory approval...
Friday Mar 09, 2007
TNF-Inhibitors Cut Cancer, Cardiac, Overall Mortality in RA Patients
A comparison of two nationwide databases shows that RA patients treated with TNF-inhibitors have lower mortality from all causes than RA patients not taking these drugs...
Thursday Jan 25, 2007
Questions Raised About Study That Links SSRIs to Doubling of Fracture Risk in Elderly
A cohort study of minimal trauma fractures in community-dwelling elderly patients recently concluded that daily use of SSRI antidepressants doubles fracture risk, but the data may not be strong enough to justify that conclusion...
Thursday Sep 07, 2006
Overall Lupus Mortality Drops, but SLE Cardiovascular Death Rates Increase
As death rates continue to plummet in systemic lupus erythematosus (SLE), physicians need to treat cardiovascular symptoms aggressively while balancing the need for immune suppressant therapy against the risk of fatal infection... Bernatsky S, et al. Arthritis Rheum. 2006;54:2550-2557
Thursday Jun 22, 2006
EULAR Lupus Guidelines Make the Best of Sparse Data
While EULAR experts agree on the best treatment of SLE and recommend an integrated approach to medical care, the lupus task force also warns of a worrying lack of evidence on the benefits of lifestyle modifications and the impact of primary preventive measures... Boumpas D. 2006 EULAR Meeting.
Friday Apr 14, 2006
Low Risk of Serious Infections With Infliximab When Used at Approved Dose of 3 mg/kg
New research suggests that the risk of serious infections in RA patients given the approved infliximab dose of 3 mg/kg plus methotrexate (MTX) is similar to the risk among patients receiving MTX alone... Westhovens R, et al. Arthritis Rheum. 2006;54:1075-1086.
Thursday Nov 17, 2005
Febuxostat Superior to Allopurinol for Hyperuricemia in Gouty Arthritis
The next-generation nonpurine selective xanthine oxidase inhibitor febuxostat, the first new agent for gout in 40 years, proved to be significantly more potent than allopurinol for lowering serum uric acid to <6.0 mg/dL, a level associated with a dissolution of the urate crystals that cause gouty arthritis and a reduction in tophus size ... Annual Meeting of the American College of Rheumatology; November 12–17, 2005; San Diego, Calif.
Friday Aug 05, 2005
RA Patients With High BMI Have Lower Mortality
In a finding that runs contrary to the recognized relationship between increased weight and mortality, a new study has found that rheumatoid arthritis (RA) patients with a high body mass index had a lower risk of death than their leaner counterparts... Escalante A, Haas RW, del Rincón I. Arch Intern Med. 2005;165:1624-1629.
Wednesday Jul 06, 2005
Radiological Grade, High Global Assessment, and Past NSAID Use Strongly Predictive of Hip OA Joint Replacement
Patients with OA of the hip who presented with a radiological grade of III or IV, a high mean global assessment during the first 6 months, and previous treatment with NSAIDs have a stronger likelihood of undergoing total hip replacement surgery... Ann Rheum Dis. 2005;64:1028-1032
Friday Jun 10, 2005
Treatment of RA Reduces Cardiovascular Mortality
Analysis of a large RA database reveals that treatment with MTX or anti-TNF-α drugs causes a significant decrease in mortality, specifically in death due to cardiovascular and pulmonary disease... Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Sunday Mar 13, 2005
Markers of Systemic Inflammation May Be Independent Risk Factors for Cardiovascular Death in Patients With Rheumatoid Arthritis
A new study indicates that ESR may be predictive of CV mortality and suggests that tighter control of inflammation may help improve long-term outcomes for RA patients...Maradit-Kremers H, et al. Arthritis Rheum. 2005;52:722-732.
Tuesday Jan 25, 2005
Three New Studies Further Elucidate Risks and Benefits of Coxibs
Newly published study findings from CRESCENT show that rofecoxib significantly increases 24-hour blood pressure after 6 weeks of therapy, while celecoxib and naproxen do not; two other published studies address COX-2 risks and benefits... Sowers JR, et al. Arch Intern Med. 2005;165:161-168.
Friday Dec 03, 2004
Leflunomide Associated With Lower Rate of Adverse Events Than Other DMARDs, Large Cohort Study Finds
Study of more than 40,000 patients showed that the AE profile of leflunomide, alone or in combination with methotrexate, was comparable to that of other DMARDs used in the treatment of rheumatoid arthritis...Cannon GW. J Rheumatol. 2004;31:1906-1911.
Tuesday Oct 19, 2004
Studies of TNF-Alpha Blockers in Rheumatoid Arthritis Focus on Understanding Safety Issues
A new postmarketing surveillance analysis shows that infliximab is safe at approved doses, and patients have no greater risk of infection than those taking methotrexate ... Yocum DE et al. Presented at: Annual Meeting of the American College of Rheumatology; October 19, 2004; San Antonio, Tex.
|
